<p><sup>a</sup> Because vaccine effectiveness (VE) for 2009–2010 and 2010–2011 epidemics were estimated using different vaccination coverage sources (administrative source <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0065919#pone.0065919-Vaux1" target="_blank">[44]</a> and from GPs practices respectively) and strata (week for 2009–2010 and risk-group for influenza for 2010–2011 epidemic) we did not shown these VE estimated values in this study. <sup>b</sup> Indicate the viral dominant type or subtype when it differs from the vaccine strain for the season. Only mismatch with dominant type is considered. ‘–‘ indicate the circulating strains were close to the vaccine’s ones. <sup>c</sup> One of the 2 circulating A(H3N2...
BackgroundInfluenza vaccination is recommended for all US residents aged ≥6 months. Vaccine effectiv...
Background During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were ...
<div><h3>Background</h3><p>Many novel vaccines can cover only a fraction of all antigenic types of a...
Influenza vaccine effectiveness (IVE) varies over different influenza seasons and virus (sub)types/l...
Influenza vaccine effectiveness (IVE) varies over different influenza seasons and virus (sub) types/...
Background. Influenza vaccines may be reformulated annually because of antigenic drift in influenza ...
Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a mul...
Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a mul...
Estimation of influenza vaccine effectiveness (VE) is complicated by various degrees of mismatch bet...
Background. We estimate vaccine effectiveness (VE) against both influenza A/subtypes and B/lineages ...
In this study, we assess how effective pandemic and trivalent 2009-2010 seasonal vaccines were in pr...
Background. During the 2012–2013 influenza season, there was cocirculation of influenza A(H3N2) and ...
BACKGROUND: Influenza vaccines are licensed annually based on immunogenicity studies. We used five s...
Influenza vaccines are updated every year to match the vaccine strains with currently circulating vi...
Introduction Influenza A(H3N2) viruses predominated in Europe in 2016–17. In 2017–18 A(H3N2) and A ...
BackgroundInfluenza vaccination is recommended for all US residents aged ≥6 months. Vaccine effectiv...
Background During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were ...
<div><h3>Background</h3><p>Many novel vaccines can cover only a fraction of all antigenic types of a...
Influenza vaccine effectiveness (IVE) varies over different influenza seasons and virus (sub)types/l...
Influenza vaccine effectiveness (IVE) varies over different influenza seasons and virus (sub) types/...
Background. Influenza vaccines may be reformulated annually because of antigenic drift in influenza ...
Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a mul...
Influenza A(H3N2), A(H1N1)pdm09 and B viruses co-circulated in Europe in 2014/15. We undertook a mul...
Estimation of influenza vaccine effectiveness (VE) is complicated by various degrees of mismatch bet...
Background. We estimate vaccine effectiveness (VE) against both influenza A/subtypes and B/lineages ...
In this study, we assess how effective pandemic and trivalent 2009-2010 seasonal vaccines were in pr...
Background. During the 2012–2013 influenza season, there was cocirculation of influenza A(H3N2) and ...
BACKGROUND: Influenza vaccines are licensed annually based on immunogenicity studies. We used five s...
Influenza vaccines are updated every year to match the vaccine strains with currently circulating vi...
Introduction Influenza A(H3N2) viruses predominated in Europe in 2016–17. In 2017–18 A(H3N2) and A ...
BackgroundInfluenza vaccination is recommended for all US residents aged ≥6 months. Vaccine effectiv...
Background During the 2015/16 influenza season in Europe, the cocirculating influenza viruses were ...
<div><h3>Background</h3><p>Many novel vaccines can cover only a fraction of all antigenic types of a...